# Terapio Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/terapio

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.terapio.com
- Total disclosed funding: $5M
- Latest round: Series B (Jul 21, 2015)
- Investors on record: 1

## About

Terapio Corporation is a medical technology company specializing in innovative pain relief solutions through Smart TENS units, designed for efficient pain management and user convenience.Founded in 2005 and headquartered in Austin, US, Terapio Corporation focuses on developing advanced medical devices. The company's funding history includes a Series A round in July 2015, led by Sante Ventures, raising a total of USD 5.00 mn. The CEO, Nathalia De Figuereido, leads the organization towards its vision in the healthcare industry.Terapio+ specializes in the design and manufacture of Smart TENS (Transcutaneous Electrical Nerve Stimulation) units, which are certified medical devices aimed at providing temporary relief from chronic or acute pain. The core product offerings include a Wireless Smart TENS unit with 15 therapeutic settings and 16 intensity levels, allowing users to manage mild to severe pain discreetly while on the go. Additionally, the company offers a 3-in-1 TENS unit that incorporates over 50 therapeutic programs and dual-channel delivery for enhanced relief, as well as a Circulation TENS unit specifically designed to alleviate discomfort in the legs and feet. Terapio+ targets a diverse customer base across multiple geographical regions, focusing on areas with high demand for innovative pain relief solutions.Terapio+ generates revenue through direct-to-consumer sales of its TENS units, structured around a model that emphasizes accessibility and ease of use for end users. The company engages customers through its online platform, providing pricing options for its flagship products. Each Smart TENS unit is priced to ensure affordability while maintaining high-quality standards. Transactions typically occur as one-time purchases, allowing consumers to buy devices outright without subscription commitments, thereby facilitating straightforward purchasing decisions. This direct approach fosters a strong relationship with individual consumers and positions Terapio+ for potential partnerships with healthcare providers and wellness retailers in the future.Terapio Corporation plans to leverage the recent Series A funding of USD 5.00 mn raised in July 2015 to enhance product development and market expansion. The company is designing new Smart TENS products to cater to a wider array of pain management needs, with launch dates set for later this year. Additionally, Terapio+ aims to expand into new geographic markets, including Europe and Asia, by 2024, focusing on areas with increasing demand for pain relief solutions. The funding will be utilized to support these initiatives, ensuring that Terapio+ remains competitive in the evolving healthcare landscape.

## Funding rounds

- Series B, Jul 21, 2015 — Sante Ventures
- Series A, Nov 12, 2009, $5M — Sante Ventures

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A, Series B